Our study suggested that highly-expressed CTSB in gliomas was closely associated with the malignant pathological subtypes, poor prognosis, tumor-infiltrating immune cells and immunosuppression, which made it a promising biomarker and potential target in the diagnosis, treatment and prognostic assessment of gliomas. The gene discussed is CTSB; the disease is glioma.